We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Axelar AB Appoints Carl Harald Janson as CEO
News

Axelar AB Appoints Carl Harald Janson as CEO

Axelar AB Appoints Carl Harald Janson as CEO
News

Axelar AB Appoints Carl Harald Janson as CEO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Axelar AB Appoints Carl Harald Janson as CEO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Axelar AB has announced the appointment of Carl Harald Janson as new CEO.

“We are very pleased to have appointed Carl Harald Janson as our new CEO in Axelar AB”, says Göran Pettersson, Chairman of Axelar.

Pettersson continued, “Carl Harald has previously been a Member of the Board of Axelar. His broad experience in pharmaceutical development will be of great benefit to the company. Johan Harmenberg, CEO of Axelar since 2007, will continue as Chief Medical Officer.”

“I am excited to lead the experienced team of Axelar and to continue the development of AXL1717. I look forward to take this potential novel cancer treatment to proof-of-concept”, says Carl Harald Janson.

Janson continued, “I am also very pleased that Johan Harmenberg will continue as Chief Medical Officer.”

Carl Harald Janson also serves as CEO of Karolinska Developments fully owned oncology group KDev Oncology AB which includes Akinion Pharmaceuticals AB and GliGene AB.

He previously worked as Vice President Portfolio Management at Karolinska Development from 2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a Certified European Financial Analyst (CEFA) from Stockholm School of Economics.

Carl Harald has over 25 years of experience in medicine, pharmaceutical development and asset management at Astra Arcus, Danske Securities and Carnegie Investment Bank.

He currently serves as Board Director of Clanotech AB and Akinion Pharmaceuticals AB.

Advertisement